Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens
Status: Enrolling
Updated:  12/31/1969
Hosp. of the Univ. of Pennsylvania CRS
2371
mi
from 98109
Philadelphia, PA
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens
Status: Enrolling
Updated: 12/31/1969
Hosp. of the Univ. of Pennsylvania CRS
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens
Status: Enrolling
Updated:  12/31/1969
Pitt CRS
2134
mi
from 98109
Pittsburgh, PA
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens
Status: Enrolling
Updated: 12/31/1969
Pitt CRS
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens
Status: Enrolling
Updated:  12/31/1969
University of Washington AIDS CRS
2
mi
from 98109
Seattle, WA
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens
Status: Enrolling
Updated: 12/31/1969
University of Washington AIDS CRS
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients
A Phase I/II Study Of the Safety, Survival, and Trafficking of Autologous CD4-ZETA Gene-Modified T Cells With and Without Extension Interleukin-2 in HIV Infected Patients
Status: Enrolling
Updated:  12/31/1969
Walter Reed Army Medical Center
2322
mi
from 98109
Washington,
CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients
A Phase I/II Study Of the Safety, Survival, and Trafficking of Autologous CD4-ZETA Gene-Modified T Cells With and Without Extension Interleukin-2 in HIV Infected Patients
Status: Enrolling
Updated: 12/31/1969
Walter Reed Army Medical Center
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Usc La Nichd Crs
961
mi
from 98109
Alhambra, CA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Usc La Nichd Crs
961
mi
from 98109
Alhambra, CA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Miller Children's Hosp. Long Beach CA NICHD CRS
979
mi
from 98109
Long Beach, CA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Miller Children's Hosp. Long Beach CA NICHD CRS
979
mi
from 98109
Long Beach, CA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS
979
mi
from 98109
Los Angeles, CA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS
979
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Orange County
984
mi
from 98109
Orange, CA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Orange County
984
mi
from 98109
Orange, CA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
UCSD Mother-Child-Adolescent Program CRS
1063
mi
from 98109
San Diego, CA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
UCSD Mother-Child-Adolescent Program CRS
1063
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Univ. of California San Francisco NICHD CRS
682
mi
from 98109
San Francisco, CA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Univ. of California San Francisco NICHD CRS
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Univ. of Colorado Denver NICHD CRS
1026
mi
from 98109
Aurora, CO
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Univ. of Colorado Denver NICHD CRS
1026
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Connecticut Children's Medical Center
2429
mi
from 98109
Hartford, CT
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Connecticut Children's Medical Center
2429
mi
from 98109
Hartford, CT
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's National Med. Ctr. Washington DC NICHD CRS
2322
mi
from 98109
Washington,
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's National Med. Ctr. Washington DC NICHD CRS
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Howard Univ. Washington DC NICHD CRS
2322
mi
from 98109
Washington,
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Howard Univ. Washington DC NICHD CRS
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
South Florida CDTC Ft Lauderdale NICHD CRS
2719
mi
from 98109
Fort Lauderdale, FL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
South Florida CDTC Ft Lauderdale NICHD CRS
2719
mi
from 98109
Fort Lauderdale, FL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Univ. of Florida Jacksonville NICHD CRS
2449
mi
from 98109
Jacksonville, FL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Univ. of Florida Jacksonville NICHD CRS
2449
mi
from 98109
Jacksonville, FL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Univ. of Miami Ped. Perinatal HIV/AIDS CRS
2730
mi
from 98109
Miami, FL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Univ. of Miami Ped. Perinatal HIV/AIDS CRS
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program
1732
mi
from 98109
Chicago, IL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program
1732
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Rush Univ. Cook County Hosp. Chicago NICHD CRS
1730
mi
from 98109
Chicago, IL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Rush Univ. Cook County Hosp. Chicago NICHD CRS
1730
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Chicago Children's CRS
1730
mi
from 98109
Chicago, IL
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Chicago Children's CRS
1730
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's Hospital
2097
mi
from 98109
New Orleans, LA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's Hospital
2097
mi
from 98109
New Orleans, LA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's Hosp. of Boston NICHD CRS
2485
mi
from 98109
Boston, MA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's Hosp. of Boston NICHD CRS
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Boston Medical Center Ped. HIV Program NICHD CRS
2485
mi
from 98109
Boston, MA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Boston Medical Center Ped. HIV Program NICHD CRS
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
WNE Maternal Pediatric Adolescent AIDS CRS
2456
mi
from 98109
Worcester, MA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
WNE Maternal Pediatric Adolescent AIDS CRS
2456
mi
from 98109
Worcester, MA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Michigan NICHD CRS
1932
mi
from 98109
Detroit, MI
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Michigan NICHD CRS
1932
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Rutgers - New Jersey Medical School CRS
2392
mi
from 98109
Newark, NJ
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Rutgers - New Jersey Medical School CRS
2392
mi
from 98109
Newark, NJ
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Bronx-Lebanon CRS
2402
mi
from 98109
Bronx, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Bronx-Lebanon CRS
2402
mi
from 98109
Bronx, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Jacobi Med. Ctr. Bronx NICHD CRS
2405
mi
from 98109
Bronx, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Jacobi Med. Ctr. Bronx NICHD CRS
2405
mi
from 98109
Bronx, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS
mi
from 98109
Brooklyn, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS
mi
from 98109
Brooklyn, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Nyu Ny Nichd Crs
2402
mi
from 98109
New York, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Nyu Ny Nichd Crs
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Strong Memorial Hospital Rochester NY NICHD CRS
2161
mi
from 98109
Rochester, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Strong Memorial Hospital Rochester NY NICHD CRS
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
SUNY Stony Brook NICHD CRS
2458
mi
from 98109
Stony Brook, NY
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
SUNY Stony Brook NICHD CRS
2458
mi
from 98109
Stony Brook, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
DUMC Ped. CRS
2341
mi
from 98109
Durham, NC
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
DUMC Ped. CRS
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
St. Jude/UTHSC CRS
1864
mi
from 98109
Memphis, TN
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
St. Jude/UTHSC CRS
1864
mi
from 98109
Memphis, TN
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hosp. CRS
1892
mi
from 98109
Houston, TX
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hosp. CRS
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital CRS
2
mi
from 98109
Seattle, WA
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital CRS
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated:  12/31/1969
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS
3726
mi
from 98109
San Juan,
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age
Status: Enrolling
Updated: 12/31/1969
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS
3726
mi
from 98109
San Juan,
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Usc Crs
962
mi
from 98109
Los Angeles, CA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Usc Crs
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Center CRS
960
mi
from 98109
Los Angeles, CA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS
960
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Stanford CRS
707
mi
from 98109
Palo Alto, CA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Stanford CRS
707
mi
from 98109
Palo Alto, CA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Ucsd, Avrc Crs
1063
mi
from 98109
San Diego, CA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Ucsd, Avrc Crs
1063
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Harbor-UCLA Med. Ctr. CRS
976
mi
from 98109
Torrance, CA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Harbor-UCLA Med. Ctr. CRS
976
mi
from 98109
Torrance, CA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
University of Miami AIDS CRS
2730
mi
from 98109
Miami, FL
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
University of Miami AIDS CRS
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
The Ponce de Leon Ctr. CRS
2178
mi
from 98109
Atlanta, GA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
The Ponce de Leon Ctr. CRS
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
IHV Baltimore Treatment CRS
2327
mi
from 98109
Baltimore, MD
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
IHV Baltimore Treatment CRS
2327
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Bmc Actg Crs
2485
mi
from 98109
Boston, MA
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Bmc Actg Crs
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Washington U CRS
1717
mi
from 98109
Saint Louis, MO
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Washington U CRS
1717
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
NY Univ. HIV/AIDS CRS
2402
mi
from 98109
New York, NY
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
NY Univ. HIV/AIDS CRS
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Columbia P&S CRS
2400
mi
from 98109
New York, NY
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Columbia P&S CRS
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated:  12/31/1969
Trillium Health ACTG CRS
2162
mi
from 98109
Rochester, NY
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less
Status: Enrolling
Updated: 12/31/1969
Trillium Health ACTG CRS
2162
mi
from 98109
Rochester, NY
Click here to add this to my saved trials